Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 33 Publications

6 Customer Reviews

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M4LQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi5[2NKSzVyPUCuNFI5ODZizszN NHXiRYhUSU6JRWK=
KS-1 NV3nfWF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzSTWM2OD1yLkCzPFM2KM7:TR?= NWf0NoZMW0GQR1XS
TE-11 NF7aR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWxPFZJUUN3ME2wMlA4QDJ{IN88US=> M2LMeXNCVkeHUh?=
EW-1 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rMSmlEPTB;MD6wPFU5PSEQvF2= M{LIenNCVkeHUh?=
HMV-II NEPpWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;admlEPTB;MD6wPFg1PiEQvF2= MXLTRW5ITVJ?
COLO-205 NWLQZ2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7KV4dKSzVyPUCuNVA1PTRizszN NIPkeo5USU6JRWK=
ES1 M1\rOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvRUWRLUUN3ME2wMlExPjl4IN88US=> M3fOc3NCVkeHUh?=
GDM-1 NXXpfGw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMUO2O|Ih|ryP M37JTnNCVkeHUh?=
ML-2 NEm1XXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMUW4PVYh|ryP MY\TRW5ITVJ?
Saos-2 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMU[1NlYh|ryP MWDTRW5ITVJ?
NCI-H1355 M1rRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvJTWM2OD1yLkG4NVM2KM7:TR?= NF3LNI5USU6JRWK=
G-401 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMUiyN{DPxE1? M{[4VHNCVkeHUh?=
EW-16 NEP0ZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluwTWM2OD1yLkG4O|c4KM7:TR?= NWfqe2NiW0GQR1XS
EW-7 M3fKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PTfGlEPTB;MD6xPFg5OSEQvF2= NUi0ZZNiW0GQR1XS
NCI-H727 NVnxdY1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonBTWM2OD1yLkG5O|k1KM7:TR?= NGT4VnNUSU6JRWK=
LCLC-97TM1 M3vsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMkC5OVUh|ryP NXXyfY5TW0GQR1XS
NCI-H650 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLHTWM2OD1yLkKxN|g1KM7:TR?= MV7TRW5ITVJ?
NCI-H2122 NH7TbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLEUWdPUUN3ME2wMlI{Ojl7IN88US=> MkLjV2FPT0WU
SK-N-DZ NHzXSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPyeYEyUUN3ME2wMlI{Pjl6IN88US=> MlXTV2FPT0WU
HT-29 M1L4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMkSyOFgh|ryP MULTRW5ITVJ?
LB771-HNC M{PBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPY[oh7UUN3ME2wMlI2QTF3IN88US=> M1HBdHNCVkeHUh?=
HT-144 M3S2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH1TWM2OD1yLkK2NVkyKM7:TR?= NELpOGtUSU6JRWK=
LAN-6 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7Z[IVKSzVyPUCuNlY{PDhizszN MmfVV2FPT0WU
EW-18 NUOzS|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXPXFdKSzVyPUCuNlcxODFizszN MlLFV2FPT0WU
LS-1034 Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr0b2NKSzVyPUCuNlcyOzJizszN MnHoV2FPT0WU
EW-11 NHH5dpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjONJRWUUN3ME2wMlI5PDN{IN88US=> Mm[5V2FPT0WU
SNU-C1 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjiTWM2OD1yLkK5N|E{KM7:TR?= NIrVd5BUSU6JRWK=
RS4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOzRZlKSzVyPUCuN|M4PThizszN M2DVPHNCVkeHUh?=
ES4 NWPhfIxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnsTWM2OD1yLkSxNFM5KM7:TR?= M1K1NnNCVkeHUh?=
COLO-320-HSR NV;xcY1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nBdGlEPTB;MD60NVM3QCEQvF2= NXm5Z2tnW0GQR1XS
NB10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3EVo5bUUN3ME2wMlQ2PDN5IN88US=> NWrIeHRxW0GQR1XS
BFTC-905 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPLTWM2OD1yLkS2O|U5KM7:TR?= M4rp[XNCVkeHUh?=
A375 NX\oNHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH36dItKSzVyPUCuOFc3OTdizszN Ml3YV2FPT0WU
SJRH30 NGmzNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jQXGlEPTB;MD61NFgzOiEQvF2= MWLTRW5ITVJ?
NOS-1 NVn5ZW9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwNUKyOlch|ryP MU\TRW5ITVJ?
SIG-M5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFc|VNUUN3ME2wMlU{PTV5IN88US=> M2rKUHNCVkeHUh?=
DOK M3HtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH4PWhCUUN3ME2wMlU2PiEQvF2= NHrQRoVUSU6JRWK=
NB69 NX\5SYc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwNUiyOVch|ryP MofnV2FPT0WU
SK-NEP-1 M4[0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTHSHZKSzVyPUCuOlAzOzZizszN NILmdoNUSU6JRWK=
SK-MM-2 M{HRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNkW0PVEh|ryP M1f6[nNCVkeHUh?=
NCI-H358 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXLWVdKSzVyPUCuOlcxQDJizszN NIDmWmVUSU6JRWK=
RH-1 M1m3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zi[GlEPTB;MD63OFg2QSEQvF2= NF;yV49USU6JRWK=
NH-12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TpfmlEPTB;MD63OlA1PiEQvF2= NG\w[nZUSU6JRWK=
TE-12 M4SweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH3SZU6UUN3ME2wMlc3PDh4IN88US=> MV;TRW5ITVJ?
COLO-668 M4\RW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwOES2OlYh|ryP MX\TRW5ITVJ?
PANC-08-13 NEjLPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfaUW1KSzVyPUCuPFY{PzdizszN NVnSTlN6W0GQR1XS
HCC2998 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHXWFBKSzVyPUCuPFgzPjNizszN MYrTRW5ITVJ?
ABC-1 NET1cW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjGdmZKSzVyPUCuPVA{PTJizszN NHXzSWRUSU6JRWK=
ES6 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwOUGwOlYh|ryP NIjpTJJUSU6JRWK=
SNU-387 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwOUmzPVMh|ryP MoDFV2FPT0WU
CMK MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTOTWM2OD1yLkm5PVI6KM7:TR?= NGnXdWJUSU6JRWK=
SJSA-1 M2D4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfqUW1uUUN3ME2xMlA{PjV|IN88US=> M16ydXNCVkeHUh?=
SIMA MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v2fGlEPTB;MT6wOlgzPSEQvF2= NFHjVVVUSU6JRWK=
ES3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwMUKyPVch|ryP MXzTRW5ITVJ?
IGROV-1 NYDlU3VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPvO41KSzVyPUGuNVU1PDRizszN M{jz[HNCVkeHUh?=
MEL-JUSO NGjGdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\OdZdKSzVyPUGuNVU4PTlizszN Ml7PV2FPT0WU
T84 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xb4lKSzVyPUGuNlA6OTRizszN MnfkV2FPT0WU
CAL-85-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fUTmlEPTB;MT6yN|E{QCEQvF2= M1fPNnNCVkeHUh?=
RD M3T5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi1TZZKSzVyPUGuNlY1PTVizszN M1Oxb3NCVkeHUh?=
TE-8 NGXae|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzF[ZlKUUN3ME2xMlMyPDZ{IN88US=> M3;MNnNCVkeHUh?=
L-363 M1jFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwM{SyNFgh|ryP M4PYWnNCVkeHUh?=
EKVX NEPOVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwM{S1Olgh|ryP M4nNUnNCVkeHUh?=
SK-MEL-3 M2roNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjxTWM2OD1zLkS4OVU3KM7:TR?= NXzte3Z1W0GQR1XS
TGBC24TKB NHn2eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T5SWlEPTB;MT61NFE6OyEQvF2= MXnTRW5ITVJ?
NCI-H1770 NV76c5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFwNUGxNVMh|ryP MX;TRW5ITVJ?
HuH-7 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILETlNKSzVyPUGuOlAxQThizszN M1TaRXNCVkeHUh?=
HL-60 NGK2Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO2TWM2OD1zLk[2PVI5KM7:TR?= NWXvOIprW0GQR1XS
TE-1 M1\LOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnFTWM2OD1zLkewPVQ2KM7:TR?= M4TTNHNCVkeHUh?=
LC-2-ad Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3NZ21ZUUN3ME2xMlc{QDh5IN88US=> M{X0SHNCVkeHUh?=
LB647-SCLC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjMZ|FVUUN3ME2xMlc3PTh|IN88US=> MUDTRW5ITVJ?
NCI-H2171 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHBTWM2OD1zLke3O|E3KM7:TR?= NXzYXoxSW0GQR1XS
SK-PN-DW Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13oVmlEPTB;MT65NVI6QCEQvF2= MYDTRW5ITVJ?
MC-IXC M{HT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELMcVhKSzVyPUGuPVg6QCEQvF2= MXzTRW5ITVJ?
LS-513 NUTEO|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnITWM2OD1{LkC1N|A2KM7:TR?= Mnj1V2FPT0WU
EW-3 MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjXN4NxUUN3ME2yMlA6QDR2IN88US=> MULTRW5ITVJ?
OPM-2 M2K2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT0Uoh4UUN3ME2yMlExOiEQvF2= M4nNSHNCVkeHUh?=
LP-1 NE[0VnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M132bGlEPTB;Mj6yOVgxPyEQvF2= M1HrS3NCVkeHUh?=
LU-134-A MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvuTWM2OD1{LkK3O{DPxE1? NXS3TVRJW0GQR1XS
CP66-MEL NXPP[ZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJwMkmwNVQh|ryP NG\xSWNUSU6JRWK=
HCC1143 NGXyZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwNEWzOlgh|ryP NVzUNZBUW0GQR1XS
LOXIMVI NYLscopST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHXR4tKSzVyPUKuOlAzOSEQvF2= NGnTVmlUSU6JRWK=
TE-10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwN{C4N|gh|ryP MW\TRW5ITVJ?
NCI-H1882 NXe0Z|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfPU|RKSzVyPUKuO|UzOjdizszN NUK0PHVVW0GQR1XS
CHP-126 M3fWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDKTWM2OD1{Lke2N|E4KM7:TR?= MXrTRW5ITVJ?
NCI-H1623 M3rlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\XcWlEPTB;Mj65NlAzPCEQvF2= NH;aWJNUSU6JRWK=
GB-1 M4\xRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrpTWM2OD1{LkmzOFA1KM7:TR?= NGTiR4RUSU6JRWK=
RCC10RGB MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfjZWNKSzVyPUKuPVUzQDFizszN NXzZboxsW0GQR1XS
NCI-H2141 M2\kbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJwOU[4PVYh|ryP MYXTRW5ITVJ?
GI-ME-N MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnXcFNDUUN3ME2zMlAxPTZ3IN88US=> M2W5bnNCVkeHUh?=
NCI-H526 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTNTWM2OD1|LkC0NFg2KM7:TR?= MXfTRW5ITVJ?
NCI-H747 NYnpXVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHR[2ROUUN3ME2zMlA1QTl{IN88US=> MV\TRW5ITVJ?
SNU-423 NVr4OXBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\vPG5iUUN3ME2zMlIxOzF|IN88US=> M1fIVnNCVkeHUh?=
A427 NEfGfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ewXGlEPTB;Mz6yOVY6QSEQvF2= Mkj3V2FPT0WU
CAL-12T NXf3col5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNwNEC3NVMh|ryP MUnTRW5ITVJ?
LU-99A MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvDTWM2OD1|LkS3NVA2KM7:TR?= MYDTRW5ITVJ?
MS-1 NHvERW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDsTWM2OD1|LkWzOFI6KM7:TR?= MU\TRW5ITVJ?
SK-LU-1 M2G3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C3UmlEPTB;Mz63OlI6PSEQvF2= M4H2N3NCVkeHUh?=
SW837 M2LLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf0TWM2OD1|Lke2N|M{KM7:TR?= NILTVplUSU6JRWK=
ES8 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;QZXhKSzVyPUOuPFM5PzdizszN NVHOSo5PW0GQR1XS
MZ2-MEL Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkiyTWM2OD1|LkmyNFg3KM7:TR?= NHq5UHNUSU6JRWK=
TGW MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\4XlVKSzVyPUSuNFE{OTFizszN NWnMUnAyW0GQR1XS
GP5d Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLhTWM2OD12LkC1N|YzKM7:TR?= M3[zOHNCVkeHUh?=
BB49-HNC NFfBeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vCdWlEPTB;ND6xOVIyOyEQvF2= M{\kRnNCVkeHUh?=
NB13 NWrienNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrBO4lKSzVyPUSuNlY5QDdizszN NVLZXZFmW0GQR1XS
NTERA-S-cl-D1 NIPxR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmw[pJKSzVyPUSuNlg3OTVizszN NFLFcY9USU6JRWK=
NCI-H1648 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvqRZluUUN3ME20MlI6QDF7IN88US=> MnXyV2FPT0WU
LCLC-103H M3n3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKwbphQUUN3ME20MlMzOTl3IN88US=> MUnTRW5ITVJ?
LS-411N MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRwNES4PFUh|ryP MkHpV2FPT0WU
NCI-H1092 M1H4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe5dWpKSzVyPUSuOFU3QDdizszN NXy1eZlGW0GQR1XS
PANC-10-05 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f3XmlEPTB;ND62PVg1KM7:TR?= NUnBbFhnW0GQR1XS
DK-MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[yR5pnUUN3ME20MlgxQTN|IN88US=> MV7TRW5ITVJ?
OVCAR-5 NFLOd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq2SnNKSzVyPUSuPFEzOjZizszN M161THNCVkeHUh?=
CAL-39 NXXtb4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn1dGJKSzVyPUSuPFc3PyEQvF2= Mnz6V2FPT0WU
TE-441-T NFHIdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRwOUC1N|ch|ryP M3rSU3NCVkeHUh?=
MOLT-16 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG0eJNKSzVyPUSuPVUzPTNizszN NEHJTYpUSU6JRWK=
MCF7 NYPC[2o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvBcIFKSzVyPUWuNVQ2OTdizszN M3LtW3NCVkeHUh?=
CAPAN-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDnfmVUUUN3ME21MlI2PzB5IN88US=> MULTRW5ITVJ?
PSN1 NEH3O4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPhfGViUUN3ME21MlI4OjN3IN88US=> Mli0V2FPT0WU
NCI-H292 NHXpS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\vTWM2OD13LkOwNFQ1KM7:TR?= MVnTRW5ITVJ?
CPC-N NFKxVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWzXIwzUUN3ME21MlM6PDF7IN88US=> NFrTd|lUSU6JRWK=
DoTc2-4510 M4TpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[4TWM2OD13LkS1N|cyKM7:TR?= MmjOV2FPT0WU
LB1047-RCC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELUfVdKSzVyPUWuOVU6OzNizszN M2fGOHNCVkeHUh?=
MHH-ES-1 M3vR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTVwNUm5NFch|ryP NV[4botHW0GQR1XS
NMC-G1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTVwN{CyNlch|ryP MYLTRW5ITVJ?
SW1710 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTVwN{S3OVEh|ryP NF\hOJBUSU6JRWK=
YAPC NXKxWI81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTVwN{[yNFEh|ryP M2HuUnNCVkeHUh?=
22RV1 NH7pbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTVwOECwNVkh|ryP NWDoVId4W0GQR1XS
COLO-679 NWH6cYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHJ[Y9KSzVyPUWuPFg6PDhizszN MoD6V2FPT0WU
TCCSUP M{e4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f0UWlEPTB;NT65N|I2QSEQvF2= Mm\UV2FPT0WU
C2BBe1 M{DnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvLTWM2OD13LkmzPVch|ryP NX7INZY{W0GQR1XS
TE-15 NGLjeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[2TWM2OD14LkC2OlA2KM7:TR?= M1y0d3NCVkeHUh?=
SCLC-21H MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET6bGNKSzVyPU[uNVA5PDNizszN NUfkZWdNW0GQR1XS
EoL-1-cell NWr5bmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke1TWM2OD14LkG2OVY{KM7:TR?= MUDTRW5ITVJ?
NKM-1 NYj6VHNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHmfmVKSzVyPU[uNVY4OSEQvF2= M3K3N3NCVkeHUh?=
NCI-H1304 M{fsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LvT2lEPTB;Nj6yO|QzQCEQvF2= M3TvT3NCVkeHUh?=
NB6 NX3BSWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTZwMkm2NlIh|ryP MlPvV2FPT0WU
NALM-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S5bmlEPTB;Nj6zN|I{KM7:TR?= NXHGd3dCW0GQR1XS
NCI-H522 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\NeFlKSzVyPU[uN|M{ODZizszN MU\TRW5ITVJ?
MV-4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D4NmlEPTB;Nj6zO|A4QSEQvF2= NUPzPXZGW0GQR1XS
LB2241-RCC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X0d2lEPTB;Nj6zPFY3PyEQvF2= NVfROm1wW0GQR1XS
NCI-H1417 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOzc4FKSzVyPU[uOFA5PDdizszN MXjTRW5ITVJ?
HT-1197 M2LLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r3cGlEPTB;Nj61O|EzOiEQvF2= M1LPR3NCVkeHUh?=
P30-OHK MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;QTWM2OD14Lk[yO|ch|ryP Mn3jV2FPT0WU
ALL-PO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnTbmxKSzVyPU[uO|E6OTZizszN MX;TRW5ITVJ?
OVCAR-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vxN2lEPTB;Nj63OVQxPSEQvF2= MYfTRW5ITVJ?
HCC2157 M{[w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3TVpJKSzVyPU[uO|c1PzVizszN NUXYe2NoW0GQR1XS
NCI-H838 M37pN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXjSYhKSzVyPU[uPVY1QSEQvF2= MmHqV2FPT0WU
NCI-H1299 M1fnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISwXYlKSzVyPU[uPVcxQSEQvF2= NELCfYNUSU6JRWK=
SW954 NXfTOFdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi2U2JzUUN3ME23MlIxODZ6IN88US=> Mo[2V2FPT0WU
NCI-H441 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7OPFlyUUN3ME23MlM1ODZ3IN88US=> MkjoV2FPT0WU
SK-MEL-2 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XIXmlEPTB;Nz60PFM4OyEQvF2= NFXtR2dUSU6JRWK=
KARPAS-45 M4nkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzCTWM2OD15Lk[1PVI6KM7:TR?= MmHVV2FPT0WU
CAL-54 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjGVm5KSzVyPUeuPFI6PzdizszN M2TFeHNCVkeHUh?=
KYSE-180 NUjv[mJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTdwOEi5OFEh|ryP MX;TRW5ITVJ?
NCI-H187 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S0V2lEPTB;Nz65OVk1PyEQvF2= NEfYNpNUSU6JRWK=
RT-112 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRThwMEm2O|ch|ryP MXvTRW5ITVJ?
NCI-H1437 NH3kcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO0TWM2OD16LkC5O|k2KM7:TR?= MWHTRW5ITVJ?
SNU-449 M1XDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHCcI45UUN3ME24MlI5Ojd{IN88US=> MUfTRW5ITVJ?
HCC1187 M37XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PMZmlEPTB;OD6yPVM6OSEQvF2= NYP3XmgyW0GQR1XS
NCI-H2030 NIf2W|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHyTWM2OD16LkO3O|E1KM7:TR?= Ml;QV2FPT0WU
HuO-3N1 NUHpfVZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL1e2xKSzVyPUiuN|c5PDRizszN NHj1VnJUSU6JRWK=
COLO-792 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vaW2lEPTB;OD60NVUzPyEQvF2= MYHTRW5ITVJ?
MIA-PaCa-2 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nBRWlEPTB;OD64OVUxQCEQvF2= NHrhTXhUSU6JRWK=
SK-N-FI M4rRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvxWIdKSzVyPUmuNFQzPSEQvF2= NVPWW3JOW0GQR1XS
MMAC-SF M{jldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH72doRKSzVyPUmuNFk4PTFizszN NYX2Z2hZW0GQR1XS
NCI-H28 NI\5UIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DEcmlEPTB;OT6xNFQ3QSEQvF2= M2fv[HNCVkeHUh?=
ETK-1 NVPhZ5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rMSWlEPTB;OT6yPVk4PCEQvF2= M3;nO3NCVkeHUh?=
NCI-H1993 NGfI[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LlbmlEPTB;OT60OFI3OSEQvF2= NFnSS5ZUSU6JRWK=
no-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTlwNEexNkDPxE1? MYDTRW5ITVJ?
ChaGo-K-1 M3[zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjSXphYUUN3ME25MlUyPTh|IN88US=> MlzUV2FPT0WU
NCCIT MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\nTW1KSzVyPUmuOVMyPjlizszN M3rrUXNCVkeHUh?=
SAS NGOz[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjUfZRCUUN3ME2xNE4zPDhizszN MnjsV2FPT0WU
A673 NGL0WJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFyLkO3NFQh|ryP MoLtV2FPT0WU
NCI-H1522 NXzPco1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFyLkO3NFch|ryP NWTnT2p7W0GQR1XS
NCI-H810 NFi3N3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLnblRKSzVyPUGwMlM6ODdizszN MX7TRW5ITVJ?
IST-MES1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFyLkS1OlQh|ryP MmflV2FPT0WU
GR-ST NVO1eJoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvYTWM2OD1zMD61NFI1KM7:TR?= NVu3cW1KW0GQR1XS
SUP-T1 NH;ZUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3JcW1KSzVyPUGwMlc{OTdizszN MkPMV2FPT0WU
NB5 NYjXVpp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPQb2JoUUN3ME2xNE46ODJ{IN88US=> NVvWNo1JW0GQR1XS
MZ1-PC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFyLkm1O|Eh|ryP M3O3b3NCVkeHUh?=
SK-CO-1 M{HQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnTTWM2OD1zMD65PVMyKM7:TR?= M{nRUXNCVkeHUh?=
Capan-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjwUnlMUUN3ME2xNU4{OTl6IN88US=> MWPTRW5ITVJ?
697 M13BNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFzLk[3OVch|ryP M{PTcnNCVkeHUh?=
REH MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXMdZdbUUN3ME2xNU44PDVzIN88US=> M2r4cnNCVkeHUh?=
GI-1 NYTLdVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXGTWM2OD1zMT64OlE2KM7:TR?= NYn1WoNXW0GQR1XS
BB65-RCC NHXmXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnw[G96UUN3ME2xNk4xQTF4IN88US=> NEfrSG9USU6JRWK=
NCI-H1651 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\LdXVKSzVyPUGyMlI1PzhizszN NILVNVRUSU6JRWK=
NCI-H1618 NYDNeoF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF{LkO5O|Yh|ryP M2rrWHNCVkeHUh?=
NCI-H2081 NV61fHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmThTWM2OD1zMj62NVQyKM7:TR?= NWPu[|ZSW0GQR1XS
GCIY MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fmeWlEPTB;MUKuO|IyOyEQvF2= NVzJO5NbW0GQR1XS
NY MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorRTWM2OD1zMz6wOlQ{KM7:TR?= NVXie5dNW0GQR1XS
PANC-03-27 NUn5e|JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;lVXJNUUN3ME2xN{4xQDB5IN88US=> NWPCXGI1W0GQR1XS
BHY NFLJ[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT6TWM2OD1zMz6yNVIyKM7:TR?= NU\6WnRoW0GQR1XS
SK-OV-3 NIf0[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;TSXBKSzVyPUGzMlM4PjNizszN M{PldnNCVkeHUh?=
5637 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfCdW5KSzVyPUGzMlc4PTlizszN M4nib3NCVkeHUh?=
LC-1F MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjpTWM2OD1zND6wN|U3KM7:TR?= MULTRW5ITVJ?
SNB75 NVvnRo06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\od2lEPTB;MUSuNFM5OyEQvF2= NHPC[2NUSU6JRWK=
CHP-212 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF2LkC0OlQh|ryP NIrjdlBUSU6JRWK=
HT-1376 M{XpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\MVWlEPTB;MUSuNVEzPiEQvF2= NHTQUVVUSU6JRWK=
MONO-MAC-6 NWH3[JRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF2LkG1NFIh|ryP M17ncnNCVkeHUh?=
CA46 NF;mT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f0b2lEPTB;MUSuNVgzPyEQvF2= M3f6S3NCVkeHUh?=
SCC-15 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlThTWM2OD1zND61OVg{KM7:TR?= MVfTRW5ITVJ?
ATN-1 NU[0eoo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSwTWM2OD1zND62OlI4KM7:TR?= MVvTRW5ITVJ?
NCI-H2405 M{H6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HzOWlEPTB;MUSuPFE2PyEQvF2= NYC0SHBtW0GQR1XS
NCI-H716 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF2Lki0PVMh|ryP NX[0eZg3W0GQR1XS
SW620 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF2LkmwNVQh|ryP M3jVZnNCVkeHUh?=
NCI-H226 M{j4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF2LkmwPFUh|ryP M1roZnNCVkeHUh?=
SW962 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXGTWM2OD1zND65OFMzKM7:TR?= NGq0SZJUSU6JRWK=
KYSE-150 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGizN|ZKSzVyPUG0Mlk2PSEQvF2= MUfTRW5ITVJ?
OCUB-M M3LC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KyWGlEPTB;MUSuPVg5OyEQvF2= NEHVOXJUSU6JRWK=
ES7 NGW4V5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDIRlBKSzVyPUG1MlA6QDRizszN M3\sUHNCVkeHUh?=
SW1463 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXWPWNFUUN3ME2xOU41OjJ|IN88US=> NGDIN5VUSU6JRWK=
CAKI-1 NFi0[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q1cWlEPTB;MUWuOVM1PiEQvF2= NUjJTlVOW0GQR1XS
MKN28 M2L4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF3LkW0O|kh|ryP Ml3oV2FPT0WU
SW13 NWG0S49JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF3Lk[xPEDPxE1? MV7TRW5ITVJ?
A3-KAW MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF3Lkm2PVch|ryP M3XMWXNCVkeHUh?=
LU-65 NV3ZUnZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DNd2lEPTB;MUWuPVc3QCEQvF2= MofIV2FPT0WU
Calu-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[zTWM2OD1zNj6wN|Y5KM7:TR?= M2PwXHNCVkeHUh?=
ST486 NF3XNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnOcYxHUUN3ME2xOk4xPDNzIN88US=> NHS5cG5USU6JRWK=
BB30-HNC M{HUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jjW2lEPTB;MU[uNVI1PiEQvF2= M4HxfnNCVkeHUh?=
EGI-1 NIqwbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF4LkS0OkDPxE1? NGXh[VVUSU6JRWK=
SH-4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;4XWlEPTB;MU[uOFc{OSEQvF2= M2[ydnNCVkeHUh?=
MN-60 M2O2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ToSGlEPTB;MUeuNlI6PyEQvF2= NV;PWGVnW0GQR1XS
MPP-89 NVrxdJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\3SZZKSzVyPUG3MlI1PTlizszN MXHTRW5ITVJ?
A2780 NGTpU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF5LkSxN|kh|ryP MU\TRW5ITVJ?
Daoy MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKyemVKSzVyPUG3MlQ3QTVizszN M1voVnNCVkeHUh?=
NCI-H2126 NHu2T2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGwTWM2OD1zNz60O|cyKM7:TR?= MULTRW5ITVJ?
NCI-H1563 M4nlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF5LkS5NVch|ryP M1zSfXNCVkeHUh?=
8-MG-BA NFf3T3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF5Lk[2OFgh|ryP MVTTRW5ITVJ?
786-0 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\6NVdKSzVyPUG3Mlg{PTNizszN NGjjSpBUSU6JRWK=
AM-38 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\xRYtKSzVyPUG3Mlk{ODZizszN NXjYOHFWW0GQR1XS
COLO-824 NHvDdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXO[2lKSzVyPUG4MlQ1OzZizszN NWL2V2RoW0GQR1XS
SK-MEL-30 NVTIWmdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rZVWlEPTB;MUiuOVA5OiEQvF2= M1LqPXNCVkeHUh?=
CESS M17a[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn1b3lKSzVyPUG4Mlc3ODlizszN M2HjWXNCVkeHUh?=
BL-70 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\pTWM2OD1zOD64NVU3KM7:TR?= M4i4[HNCVkeHUh?=
NCI-H2170 MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[wTWM2OD1zOD65NVc6KM7:TR?= MX;TRW5ITVJ?
HT-3 MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF6Lkm4N{DPxE1? M4LORXNCVkeHUh?=
BOKU MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nDXmlEPTB;MUmuNFM5OSEQvF2= M{TtV3NCVkeHUh?=
HPAF-II M33y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3sSWFSUUN3ME2xPU4{ODF3IN88US=> NUTRRoZuW0GQR1XS
KGN MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H2dWlEPTB;MUmuOFc3PSEQvF2= NYTTZplkW0GQR1XS
MC-CAR NFXtVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF7Lk[zNVMh|ryP NGrCeY9USU6JRWK=
BHT-101 NHziSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFOzO5NKSzVyPUG5Mlc4PyEQvF2= MWPTRW5ITVJ?
SW1783 NGjVbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrGNVlKSzVyPUG5Mlc5ODZizszN MoPUV2FPT0WU
KP-N-YN M{XBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJyLkCyOlIh|ryP MWLTRW5ITVJ?
LU-165 NX\hWmNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzMTWM2OD1{MD61OVcyKM7:TR?= NXXLd5AzW0GQR1XS
GOTO NI\xWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJyLk[0OVEh|ryP NF7IOmpUSU6JRWK=
EFM-19 NUDIR5ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7mV49KSzVyPUKxMlA4OTZizszN NIn1S2hUSU6JRWK=
CTV-1 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zCXWlEPTB;MkGuNVA2PCEQvF2= NGrGdGZUSU6JRWK=
HEL NGjXd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH5XJc2UUN3ME2yNU41OjF4IN88US=> MYrTRW5ITVJ?
SNU-C2B MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\JTWM2OD1{MT60NlYh|ryP MmHRV2FPT0WU
ECC4 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PvSGlEPTB;MkGuO|A4KM7:TR?= MkXwV2FPT0WU
NEC8 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\yd2VKSzVyPUKxMlg{PjhizszN MUTTRW5ITVJ?
KMOE-2 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT5N|RKSzVyPUKxMlg6OjFizszN MUXTRW5ITVJ?
NCI-H524 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj3PXB[UUN3ME2yNk4xQDB6IN88US=> MofQV2FPT0WU
WSU-NHL M173RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rST2lEPTB;MkKuNVU4PyEQvF2= MoHIV2FPT0WU
SF126 NX3OUnFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfvVHd4UUN3ME2yNk4zPDZ7IN88US=> NFGySYpUSU6JRWK=
HOP-92 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrH[4JlUUN3ME2yNk4{OTZ5IN88US=> MoHNV2FPT0WU
CTB-1 NFXVcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfMe4FLUUN3ME2yNk41Pjd5IN88US=> NFH2fVNUSU6JRWK=
KYSE-270 NWfPfWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLPOJVKSzVyPUKyMlk{PTdizszN MWnTRW5ITVJ?
SK-MEL-24 NYHKVGJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjXVG9KSzVyPUKzMlE5PyEQvF2= MUjTRW5ITVJ?
Calu-3 NIPvO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ|LkKxNlgh|ryP MXjTRW5ITVJ?
GAMG MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\jeoVRUUN3ME2yN{4zOzZ5IN88US=> NWTHeGQ6W0GQR1XS
SW1573 M{TnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ|Lke0NVUh|ryP MVzTRW5ITVJ?
MHH-NB-11 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3GXJJjUUN3ME2yOE4xOTl2IN88US=> M4POUHNCVkeHUh?=
TK10 NVjnOol{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInqWmhKSzVyPUK0MlUxOTNizszN NF3WXWVUSU6JRWK=
LB373-MEL-D MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ2Lk[wOlQh|ryP MVnTRW5ITVJ?
KALS-1 NG\W[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjMWIxKSzVyPUK0Mlc{OjdizszN NXOwVHdZW0GQR1XS
HUTU-80 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnQWHBKSzVyPUK1MlgxOzJizszN MnO5V2FPT0WU
HuP-T3 Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJ4LkG2O|Qh|ryP MnG2V2FPT0WU
OE19 NFi3TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTtTWM2OD1{Nj6yNVU{KM7:TR?= NV\Dcm9DW0GQR1XS
J82 NYPtelZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET0clhKSzVyPUK2MlI1PzFizszN NXr1VWZTW0GQR1XS
DU-4475 NUH0W4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DFeGlEPTB;Mk[uN|gyQSEQvF2= M{\oR3NCVkeHUh?=
DMS-53 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPCTWM2OD1{Nj61NVM5KM7:TR?= MVXTRW5ITVJ?
COLO-741 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fKfGlEPTB;Mk[uPFM1PCEQvF2= NWfVe|lEW0GQR1XS
SW48 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLTc3RKSzVyPUK2Mlg5OiEQvF2= NUnVfpBtW0GQR1XS
IGR-1 NF7XRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2zb|FKSzVyPUK2Mlk{OzRizszN NFfyOFFUSU6JRWK=
639-V Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ5LkCyOFUh|ryP MVHTRW5ITVJ?
LK-2 MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXZTWM2OD1{Nz60NVQyKM7:TR?= NYK4ToExW0GQR1XS
NCI-H2347 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf6c414UUN3ME2yO{46Pjl7IN88US=> NEjJ[GpUSU6JRWK=
NCI-H2228 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPlNnVNUUN3ME2yPE4xQTB3IN88US=> NGjhb4JUSU6JRWK=
LS-123 M2rEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DJeGlEPTB;MkiuNVI3OiEQvF2= NVzwW4dyW0GQR1XS
U031 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG3TWM2OD1{OD6yOVIh|ryP NGTCfpdUSU6JRWK=
NCI-H1792 NWHDclR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnEPYpJUUN3ME2yPE41PzJzIN88US=> NHvabWhUSU6JRWK=
NCI-H2087 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJ6Lke1OVIh|ryP M2T5cnNCVkeHUh?=
NCI-H2342 NXjvR205T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:5bGlKSzVyPUK5MlUzODhizszN NHrr[HlUSU6JRWK=
SW626 NIi2RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37SfmlEPTB;MkmuO|U3KM7:TR?= NG\lNWNUSU6JRWK=
LB2518-MEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPielkyUUN3ME2yPU45OTVizszN MYHTRW5ITVJ?
RXF393 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNyLkC5OVIh|ryP NXXjTFlDW0GQR1XS
LC4-1 M2LuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXBNWtKSzVyPUOwMlMxQTJizszN MlPUV2FPT0WU
NCI-H1694 NF30eIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTEdJBsUUN3ME2zNE43PjJ2IN88US=> M4TaOHNCVkeHUh?=
K5 NFrOfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPjTWM2OD1|MD65O|AzKM7:TR?= NGnmc|lUSU6JRWK=
HDLM-2 NIfoXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;5TWM2OD1|MD65O|I2KM7:TR?= MoTMV2FPT0WU
BCPAP NXixXoZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNzLkizO|kh|ryP NVj4[YFYW0GQR1XS
BC-3 M1zFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTN{LkG0NFMh|ryP M4f6UHNCVkeHUh?=
LB996-RCC NXjIZpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PPWGlEPTB;M{KuNlM2QCEQvF2= MmLWV2FPT0WU
NCI-H2009 M{nTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDLOohnUUN3ME2zNk41QThzIN88US=> MXPTRW5ITVJ?
HTC-C3 NF\SOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXFUpdKSzVyPUOzMlc2OTlizszN NXHXfWk6W0GQR1XS
LAMA-84 NF\TfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN2LkS0NFch|ryP MWXTRW5ITVJ?
CCRF-CEM Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInNbIpKSzVyPUO0MlU4OTVizszN NYXoS|BXW0GQR1XS
AN3-CA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTCR5ljUUN3ME2zOU4xPTZ6IN88US=> NY\ZW2VvW0GQR1XS
NCI-H1734 M2PYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXSOodIUUN3ME2zOU4zPTZzIN88US=> Mn\HV2FPT0WU
Ca-Ski NYLIZok2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHWTWM2OD1|NT60NVAyKM7:TR?= NFm0[mZUSU6JRWK=
U-266 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq0eIVXUUN3ME2zOU43OTF2IN88US=> M4nae3NCVkeHUh?=
SBC-5 NUP5Smh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnKc|U5UUN3ME2zOU44PzhzIN88US=> NHz4cm9USU6JRWK=
GT3TKB MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q5VWlEPTB;M{euNVE2KM7:TR?= NVnkR21iW0GQR1XS
MDA-MB-175-VII MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj1[Y8zUUN3ME2zO{4zOjR6IN88US=> MY\TRW5ITVJ?
PFSK-1 M{\N[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nOdWlEPTB;M{euNlQ{PSEQvF2= MoKxV2FPT0WU
IMR-5 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELMbZBKSzVyPUO3MlI1QDdizszN NYDTc3JoW0GQR1XS
Daudi NIrp[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonLTWM2OD1|Nz6zOVk4KM7:TR?= MX7TRW5ITVJ?
A498 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzTeVNKSzVyPUO3MlczOThizszN NXHzPWdmW0GQR1XS
SCC-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHMTWM2OD1|Nz63PFQ{KM7:TR?= NF\jOZBUSU6JRWK=
COLO-680N M1vCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn0T5BKSzVyPUO4MlI5QDVizszN Moe2V2FPT0WU
SK-MES-1 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXuRWxpUUN3ME2zPE4{OjF3IN88US=> NYXQeIZmW0GQR1XS
SR M{eyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN6LkW0PVUh|ryP MXfTRW5ITVJ?
LNCaP-Clone-FGC NWHldI5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN6LkW2N|ch|ryP M{[2UHNCVkeHUh?=
SK-HEP-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTlTWM2OD1|OD63PFIzKM7:TR?= MlvsV2FPT0WU
BPH-1 NYTheoNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqzTWM2OD1|OD64N|I6KM7:TR?= M1O3T3NCVkeHUh?=
NCI-H1755 NWjsNXBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLmOVhRUUN3ME2zPU42QDF5IN88US=> MVPTRW5ITVJ?
LXF-289 M2OyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TUdWlEPTB;M{muPFA5PCEQvF2= NW\PcWVYW0GQR1XS
SW1088 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrmTWM2OD12MD6yNVA4KM7:TR?= NHy2bpNUSU6JRWK=
MOLT-4 NFfFVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\SOnJsUUN3ME20NE4zQTBzIN88US=> NFfzdItUSU6JRWK=
AsPC-1 M1ntNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjZeoNKSzVyPUSwMlQ2QDNizszN NYD6fnZLW0GQR1XS
HOP-62 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRyLk[1Olgh|ryP M2DmeXNCVkeHUh?=
A172 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRyLki1NVEh|ryP NUXX[3d1W0GQR1XS
SN12C NHnMUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr1Z|FSUUN3ME20NE46Ozh3IN88US=> MYDTRW5ITVJ?
MDA-MB-231 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTlV3NqUUN3ME20NE46QDl6IN88US=> NYT5RZhrW0GQR1XS
RPMI-2650 M1fue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qzPGlEPTB;NEGuNVU6OyEQvF2= MYPTRW5ITVJ?
KYSE-140 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO5dWN[UUN3ME20NU45OTJ|IN88US=> M1S4NHNCVkeHUh?=
KINGS-1 NHS3T3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi5OmY{UUN3ME20Nk41Pjl5IN88US=> NUTMcXF4W0GQR1XS
HSC-3 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrsS2NKSzVyPUSyMlY3PjFizszN M3f5U3NCVkeHUh?=
PC-14 NWHGfVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTjR4tKSzVyPUSzMlE5QDJizszN M{PZ[HNCVkeHUh?=
COR-L105 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T1e2lEPTB;NEOuOlUxOiEQvF2= MljoV2FPT0WU
BE-13 M{\CUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnFSVB[UUN3ME20OE4zOzdzIN88US=> MUHTRW5ITVJ?
NCI-H661 NUC4V|R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D6bWlEPTB;NESuNlk2QCEQvF2= M1H4XHNCVkeHUh?=
IST-MEL1 NEX4ZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O1bmlEPTB;NESuN|U6QSEQvF2= NWHzRmlQW0GQR1XS
HCC1806 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTR2LkW4O|Mh|ryP NIftVmFUSU6JRWK=
COLO-800 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLDTWM2OD12ND64OFU{KM7:TR?= MkH1V2FPT0WU
IST-SL2 NGPudZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDyPHJKSzVyPUS1MlEzPDdizszN NWja[FJFW0GQR1XS
8305C M3flfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPVTWM2OD12NT6zNFkh|ryP NFnKOYZUSU6JRWK=
UACC-62 M4XIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTR4LkK4O|Uh|ryP NWnzdoExW0GQR1XS
COR-L23 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHYNGVGUUN3ME20O{4yQTlizszN M3PKOnNCVkeHUh?=
EFE-184 M{TITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jFOmlEPTB;NEeuN|g5KM7:TR?= NFXnW4JUSU6JRWK=
DMS-114 MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHNPVlKSzVyPUS3MlQyPDlizszN NYjRSYY6W0GQR1XS
KYSE-520 M3nxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nQS2lEPTB;NEiuOVMyPSEQvF2= MWDTRW5ITVJ?
SNG-M NVnYNmRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;xbY5IUUN3ME20PU41OzRizszN MWjTRW5ITVJ?
A2058 M3HlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:wTWM2OD12OT60PFg2KM7:TR?= M1qwcHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID